Carbonic anhydrase 1 (ca1) inhibitors for the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies, and as biomarker of myeloproliferative disorders and other hematopoietic malignancies

(canceled)

A biomarker, for in vitro or ex vivo use of a mveloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis,

• wherein the biomarker is a level of expression or activity of Carbonic Anhydrase 1 (CA1).

An in vitro or ex vivo method for diagnosis or follow-up of a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis in an individual, the method comprising the steps of:

• a) determining a level of expression or activity of Carbonic Anhydrase 1 (CA1) in a biological sample from the individual;
• and
• b) comparing the level of expression or activity of CA1 to a reference value, wherein an increase of the level of expression or activity of Carbonic Anbydrase 1 (CA1) is indicative of the occurrence of said the myeloproliferative disorder, acute myeloid leukemia (AML) and/or primary or secondary myelofibrosis in the individual.

An in vitro or ex vivo method for screening an active agent for treatment or prevention of a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis, the method comprising:

• a) determining a level of expression or activity of Carbonic Anhydrase 1 (CA1) in a biological sample;
• and
• b) comparing the level of expression or activity of CA1 to a reference value, wherein a decrease of the level of expression or activity of Carbonic Anhydrase 1 (CA1) in the biological sample by the active agent is indicative of efficacy of the active agent for the treatment of the myeloproliferative disorder, acute myeloid leukemia (AML) and/or primary or secondary myelofibrosis.